Brett A King Selected Research

Alopecia Areata

7/2022	Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata.
1/2021	Combination tofacitinib and oral minoxidil treatment for severe alopecia areata.
1/2021	Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease.
12/2019	IL-12/IL-23 neutralization is ineffective for alopecia areata in mice and humans.
2/2019	Ruxolitinib for the treatment of severe alopecia areata.
2/2019	Tofacitinib for the treatment of alopecia areata in preadolescent children.
1/2019	Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.
1/2018	Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: A pilot study of 10 patients.
10/2017	Lack of efficacy of apremilast in 9 patients with severe alopecia areata.
4/2017	JAK inhibitors in dermatology: The promise of a new drug class.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Brett A King Research Topics

Disease

13	Alopecia Areata 07/2022 - 01/2016
5	Alopecia (Baldness) 07/2022 - 01/2016
5	Vitiligo 01/2021 - 10/2015
5	Alopecia universalis 01/2017 - 12/2014
3	Atopic Dermatitis (Atopic Eczema) 06/2021 - 09/2015
3	Psoriasis (Pustulosis Palmaris et Plantaris) 06/2021 - 12/2014
2	Skin Diseases (Skin Disease) 06/2021 - 04/2017
2	Critical Illness (Critically Ill) 01/2021 - 09/2020
2	Inflammation (Inflammations) 01/2016 - 08/2015
1	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2021
1	COVID-19 01/2021
1	Granuloma Annulare 01/2020
1	Localized Scleroderma (Morphea) 06/2018
1	Eosinophilic Fasciitis 06/2018
1	Bullous Pemphigoid (Pemphigoid) 01/2018
1	Chronic Disease (Chronic Diseases) 01/2018
1	Keratosis 05/2017
1	Photosensitivity Disorders (Photodermatitis) 01/2017
1	Erythema Multiforme 11/2016
1	Neoplasm Metastasis (Metastasis) 03/2016
1	Melanoma (Melanoma, Malignant) 03/2016
1	Paresthesia (Dysesthesia) 08/2015
1	Delayed Hypersensitivity (Hypersensitivity, Type IV) 08/2015
1	Hyperalgesia 08/2015
1	Chemical Burns (Chemical Burn) 10/2012

Drug/Important Bio-Agent (IBA)

18	tofacitinibIBA 01/2021 - 12/2014
7	Janus Kinase InhibitorsIBA 06/2018 - 09/2015
5	SaltsIBA 07/2022 - 01/2016
2	Interleukin-12 (IL 12)IBA 06/2021 - 12/2019
2	CytokinesIBA 06/2021 - 01/2021
2	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2021 - 09/2020
2	Lipocalin-2IBA 01/2021 - 09/2020
2	Interleukin-8 (Interleukin 8)IBA 01/2021 - 09/2020
2	ResistinIBA 01/2021 - 09/2020
2	Ointments (Pastes)IBA 01/2020 - 01/2018
2	ruxolitinibIBA 02/2019 - 04/2016
1	RNA (Ribonucleic Acid)IBA 06/2021
1	Interleukin-13IBA 06/2021
1	Interleukin-4 (Interleukin 4)IBA 06/2021
1	Biomarkers (Surrogate Marker)IBA 06/2021
1	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 01/2021
1	Minoxidil (Rogaine)FDA LinkGeneric 01/2021
1	Matrix Metalloproteinases (MMPs)IBA 01/2018
1	apremilastIBA 10/2017
1	Methotrexate (Mexate)FDA LinkGeneric 05/2017
1	Isotretinoin (Accutane)FDA LinkGeneric 05/2017
1	Janus KinasesIBA 11/2016
1	Imiquimod (Aldara)FDA LinkGeneric 03/2016
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 03/2016
1	Interleukin-2 (IL2)IBA 03/2016
1	Janus Kinase 1IBA 10/2015
1	AcetoneIBA 08/2015
1	squaric acid dibutyl esterIBA 08/2015
1	Alanine (L-Alanine)FDA Link 08/2015
1	Anesthetics (Anesthetic Agents)IBA 08/2015
1	AllergensIBA 08/2015
1	Histamine (Histamine Dihydrochloride)FDA Link 08/2015
1	Acetic Acid (Vinegar)FDA LinkGeneric 10/2012

Therapy/Procedure

7	Therapeutics 01/2021 - 10/2015
1	Immunomodulation 01/2018
1	Phototherapy (Light Therapy) 01/2018
1	Rewarming 08/2015
1	Intradermal Injections 08/2015